01.30.15
AbbVie
4Q Revenues: $5.5 billion (+7%)
4Q Loss: $810 million (earnings were $1.1 billion 4Q13)
FY Revenues: $20.0 billion (+6%)
FY Earnings: $1.8 billion (earnings were $4.1 billion FY13)
Comments: Growth in the quarter was driven primarily by HUMIRA sales, up 11% to $3.4 billion. Creon sales were $151 million, up 31%. Dyslipidemia sales were $104 million, up 14%. Synagis sales were down 5% to 298 million in the quarter. AndroGel sales declined 20% to $230 million. Earnings were impacted the Shire termination. R&D expenses were $879 million in the quarter.
4Q Revenues: $5.5 billion (+7%)
4Q Loss: $810 million (earnings were $1.1 billion 4Q13)
FY Revenues: $20.0 billion (+6%)
FY Earnings: $1.8 billion (earnings were $4.1 billion FY13)
Comments: Growth in the quarter was driven primarily by HUMIRA sales, up 11% to $3.4 billion. Creon sales were $151 million, up 31%. Dyslipidemia sales were $104 million, up 14%. Synagis sales were down 5% to 298 million in the quarter. AndroGel sales declined 20% to $230 million. Earnings were impacted the Shire termination. R&D expenses were $879 million in the quarter.